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Abbreviations: HF, heart failure; HFrEF, heart failure with 
reduced ejection fraction; HR, heart rate; AF, atrial fibrillation; SR, 
sinus rhythm; pVO2, peak oxygen consumption; VE/VCO2 slope, 
ventilatory efficiency slope; RER, respiratory exchange ratio
Introduction
Heart failure (HF) is rapidly growing public health issue that is 
associated with substantial mortality and morbidity.1 Atrial fibrillation 
(AF) is the most common sustained cardiac arrhythmia in HF, leading 
to worse prognosis due to an increased thromboembolic risk (mostly 
stroke) and also, possibly, due to cardiac function impairing.2
It is known that medical therapy that reduces resting heart rate 
(HR) also lowers cardiovascular events in patients with HF, so resting 
HR is said to be a modifiable risk factor for HF.3,4 In HF patients with 
sinus rhythm (SR), it has been broadly demonstrated that lower HR 
confers better exercise capacity and prognosis.5–8 Nonetheless, in 
cases of AF, the clinical repercussion and prognosis significance of 
resting HR remains unknown. 
Thus, this study aimed to examine and compare the relationships 
between resting HR, functional capacity and outcomes in HF patients 
in AF and SR.
Methods
Selection of patients and evaluation
Single center analysis with 282 patients with HF with reduced 
ejection fraction (HFrEF) (left ventricular ejection fraction≤40%), 
that were symptomatic (New York Heart Association class II or 
III), followed in the Heart Failure Clinics of our center. All patients 
underwent a comprehensive complementary evaluation, from 2005 to 
2014. Clinical, laboratorial, electrocardiographic, echocardiographic, 
and cardiopulmonary exercise test data were prospectively collected. 
Patients under 18 years old, comorbidities that limited exercise 
(including stroke, severe peripheral artery disease or musculoskeletal 
impairment), planned coronary revascularization, planned cardiac 
surgery or previous heart transplant were excluded.
A symptom-limited treadmill cardiopulmonary exercise test was 
performed. The protocol used was the modified Bruce protocol and 
the treadmill used was GE Marquette Series 2000. Gases (including 
carbon dioxide production, oxygen uptake and minute ventilation) 
were analyzed with SensorMedics Vmax 229. The peak oxygen 
consumption (pVO2) was designated as the highest achieved during 
exercise (30-second average) and was normalized for body mass. 
Percentage of predicted pVO2 was calculated according to Hansen et 
al. The ventilatory efficiency (VE/VCO2) slope was determined using 
data acquired throughout the entire exercise. 
Follow-up and endpoint
Follow-up was performed for 60 months in all patients. Composite 
endpoint was defined as death, heart transplant not planned (during 
inotropic therapy or unplanned hospitalization due to HF worsening) 
or the need for mechanical circulatory support. Data was obtained from 
the outpatient clinic visits, medical charts review and standardized 
telephone interview to all patients (12, 36 and 60 months).
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Abstract
Background: Higher resting heart rate (HR) is associated with lower exercise capacity and 
worse prognosis in patients with heart failure (HF). However, recent studies question this 
relationship in HF patients in atrial fibrillation (AF). We aimed to examine and compare the 
relationships between resting HR, exercise capacity and outcomes in HF patients in AF and 
sinus rhythm (SR).
Methods: 282 ambulatory patients with symptomatic HF and left ventricular ejection 
fraction≤40% were divided according to rhythm status into SR and AF group. All patients 
were followed for 60 months and the combined endpoint was defined as cardiac death, 
urgent heart transplantation or need for mechanical circulatory support.
Results: In the patients enrolled (mean LVEF 27±7%), 19.1% had AF. The composite 
endpoint occurred in 24.4% during follow-up. There were no differences regarding 
maximal effort, but AF group had lower exercise capacity. In the SR group, there was an 
inverse relationship between resting HR and exercise capacity (r-0.189, p 0.004). In the 
AF group, this relationship was reversed as higher resting HR was associated with better 
exercise tolerance (r 0.314, p 0.021). Regarding outcomes, patients in SR with a resting HR 
higher than 72 bpm had higher risk of composite outcome than those with lower resting HR 
(p 0.033), but this was not evident in AF patients.
Conclusion: The impact of resting HR on exercise capacity and prognosis differed entirely 
between AF and SR, suggesting that HR control may need to be managed differently for 
AF and SR in HF patients.
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Statistical analysis
Patients were divided into two groups according to baseline 
rhythm: SR and AF. Data were expressed as percentages and 
frequencies for categorical variables and as mean±standard deviation 
for continuous variables. Normality was tested using the Shapiro-Wilk 
or Kolmogorov-Smirnov test as appropriate. Baseline characteristics 
were compared using the Mann-Whitney or Student’s t-test for 
continuous variables and the Fisher’s exact test or Chi-square test 
for categorical variables. Survival was assessed by Kaplan–Meier 
analysis and log-rank test. A p-value <0.05 was considered significant 
and the SPSS version 21 software (SPSS Inc., Chicago, Illinois) was 
used for statistical analysis.
Results
This study included 282 patients, with mean age of 53.7±12.1 
years, 75.5% were male, 19.1% had AF and 37.6% had ischemic 
cardiomyopathy. Left ventricular ejection (LVEF) was 27.4±7.3% and 
23.0% were very symptomatic (NYHA class≥II). Regarding therapy, 
96.8% were taking an angiotensin-converting enzyme inhibitor 
(ACEi) or angiotensin receptor blocker (ARB), 80.1% were on a 
beta-blocker, 68.1% on a mineralocorticoid antagonist and 26.2% had 
biventricular pacing. All patients were followed-up during 60 months 
and combined endpoint (which includes cardiac death, unplanned 
heart transplant or need for mechanical circulatory support) occurred 
in 24.4% of patients.
Rhythm status
Patients’ characteristics according to rhythm status are shown in 
Table 1. AF patients more predominantly men, were older, had higher 
BNP levels and lower Heart Failure Survival Score as compared with 
SR patients. There were no differences regarding maximal effort 
(respiratory exchange ratio), but AF group had lower pVO2 and 
higher VE/VCO2 slope.
Table 1 Baseline characteristics according to rhythm status
 Sinus rhythm (n=228) Atrial fibrillation (n=54) p
Age 52.6±12.5 58.2±9.0 0.002
Male gender 72.80% 87.00% 0.029
Ischemic aetiology 40.40% 25.90% 0.049
NYHA class III (vs. II) 14.30% 9.00% <0.001
LVEF 28.4±2.7% 28.5±0.7% 0.116
BNP 296±251 489±191 0.027
Hb 13.2±1.6 12.4±0.7 0.717
Glomerular filtration rate 71.6±11.9 67.8±31.3 0.006
Na 137.6±1.8 135.0±2.8 0.156
Resting HR 82±15 85±20 0.739
pVO2 18.6±2.0 13.0±0.4 0.001
%ppVO2 62.4±5.8% 49.0±2.8% 0.065
VE/VCO2 slope 27.3±3.6 39.3± 7.5 0.002
RER peak 1.02±0.02 1.07±0.08 0.365
HFSS 8.57±0.56 8.13±0.28 0.001
Abbreviations NYHA, New york heart association; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; Hb, haemoglobin; Na, sodium; HR, 
heart rate; pVO2, peak oxygen consumption; %ppVO2, percentage of predicted peak oxygen consumption; VE/VCO2 slope, ventilatory efficiency slope; RER, 
respiratory exchange ratio; HFSS, heart failure survival score.
Exercise capacity and prognosis
Percentage of predicted pVO2 was a strong predictor of prognosis 
in both SR and AF patients (AUC 0.798, p <0.001 and AUC 0.834, 
p<0.001, respectively).
The relationship among resting HR and percentage of predicted 
pVO2 was statistically significant in the SR group, showing an inverse 
association between resting HR and exercise capacity (Figure 1A). 
In AF patients, there was also a statistically significant relationship 
among resting HR and percentage of predicted pVO2; however, this 
relationship was reversed as higher resting HR was related to better 
exercise tolerance (Figure  1B). 
Regarding outcomes, the composite endpoint occurred in 24.4% 
during follow-up. Patients in SR with a resting HR higher than 72bpm 
worse prognosis than those with lower resting HR (Figure 2A). In AF 
patients, resting HR demonstrated an opposite effect for the composite 
endpoint though it did not achieve statistical significance (Figure 2B).
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Figure 1 Relationships between predicted peak oxygen consumption (pVO2) and resting heart rate (HR) in (A) sinus rhythm and (B) atrial fibrillation patients.
Figure 2 Kaplan-Meier analysis according to resting heart rate (HR) in (A) sinus rhythm and (B) atrial fibrillation.
Discussion
The main findings of this study were that the association among 
resting HR and percentage of predicted pVO2 and outcomes contrasted 
for patients with AF and SR.
Previous researches have examined the association between 
resting HR and exercise capacity in the overall population and in heart 
disease patients, finding an inverse association between resting HR 
and functional capacity.10–11 Moreover, resting HR has been strongly 
associated with prognosis.5,6,12
Chronic HF patients with permanent AF have worse prognosis 
when compared to those in sinus rhythm. This is due to the fact that 
new-onset AF in a chronic HF patient impairs cardiac systolic and 
diastolic function and is also an indicator of a sicker patient.13–15 
In HF patients with AF, the optimal resting ventricular rate is still 
unclear.15–18 Few studies have compared resting HR and functinoal 
capacity in AF patients. Jaber et al.19 demonstrate that resting HR was 
not associated with functional capacity in AF patients with resting 
heart rat <90 bpm. Kato et al.20 showed that the association among 
resting heart rate and functional capacity was different in SR and AF 
in the general population.20 
In our study, we clearly demonstrate that lower resting heart rate 
is related to better exercise capacity in SR patients yet, in contrary, 
in AF patients it is associated with lower exercise capacity. We also 
demonstrated that resting HR<72 bpm is associated with better 
outcomes in SR but in AF the relationship is inverse.
Therefore, the present study might explain the results of previous 
studies that showed that ventricular rates lower than 70 bpm are related 
with unfavourable prognosis in HF patients with AF21 since pVO2 is 
well known to be related with future cardiac mortality and morbidity. 
Our results also help to clarify the causes why beta-blockers titration 
was not associated with improved prognosis HFrEF patients with 
AF,22 and might also elucidate the relationship between digoxin and 
adverse events.23–25 
The pathophysiology of the association between resting heart 
failure and functional capacity and prognosis in AF patients is still 
not fully understood. Lewis et al. demonstrated that ventricular rate 
lowering in AF conferred only a small stroke volume augmentation 
yet this was counterbalanced rate reduction that conferred lower 
cardiac.26 Additional studies are needed to understand this mechanism.
Limitations
Generalization of results are limited since this is a single 
centre analysis. Nevertheless, this allowed the cardio respiratory 
exercise test protocol being homogeneous in all cases, reducing the 
interobserver variability. Also, this was a HF population with reduced 
ejection fraction (mean LVEF systolic 27.4±7.3%) who were able to 
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perform exercise and, therefore, the results may not apply to the full 
HF population. Another limitation is that there was some imbalance 
between baseline characteristics of SR and AF patients which could be 
a potential bias, though there were no differences regarding maximal 
effort during cardiopulmonary exercise test.
Conclusion
The impact of resting HR on functional capacity and outcomes 
contrasted entirely between AF and SR in HFrEF patients. This 
suggests that HR control management may need to be different for AF 
and SR in HF patients.
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